# Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

> **NCT06667154** · PHASE2 · RECRUITING · sponsor: **Aline Fusco Fares, MD** · enrollment: 33 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell
- Non-Small Cell Lung Cancer NSCLC

## Interventions

- **DRUG:** Low-dose nivolumab combined with platinum-based doublet chemotherapy

## Key facts

- **NCT ID:** NCT06667154
- **Lead sponsor:** Aline Fusco Fares, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-10
- **Primary completion:** 2025-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06667154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06667154, "Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06667154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*